Go Pro
→ Buy THIS potential Musk supplier before Wednesday (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$264.18
-0.3%		$248.48
$190.75
▼
$267.47
$467.53B0.36.83 million shs1.59 million shs
argenex SE stock logo
ARGX
argenex
$1,007.40
-3.1%		$895.14
$661.85
▼
$1,058.69
$63.19B0.46348,359 shs241,285 shs
Incyte Corporation stock logo
INCY
Incyte
$127.84
+0.0%		$116.17
$81.09
▼
$132.60
$25.93B0.761.76 million shs327,115 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$829.08
-0.6%		$697.09
$541.00
▼
$847.00
$85.37B0.21846,648 shs259,758 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+2.52%+22.96%+26.31%
argenex SE stock logo
ARGX
argenex
0.00%+22.14%+13.24%+28.93%+57.54%
Incyte Corporation stock logo
INCY
Incyte
0.00%+6.37%+8.62%+31.55%+50.29%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+3.80%+27.14%+30.55%+41.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$264.18
-0.3%		$248.48
$190.75
▼
$267.47
$467.53B0.36.83 million shs1.59 million shs
argenex SE stock logo
ARGX
argenex
$1,007.40
-3.1%		$895.14
$661.85
▼
$1,058.69
$63.19B0.46348,359 shs241,285 shs
Incyte Corporation stock logo
INCY
Incyte
$127.84
+0.0%		$116.17
$81.09
▼
$132.60
$25.93B0.761.76 million shs327,115 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$829.08
-0.6%		$697.09
$541.00
▼
$847.00
$85.37B0.21846,648 shs259,758 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+2.52%+22.96%+26.31%
argenex SE stock logo
ARGX
argenex
0.00%+22.14%+13.24%+28.93%+57.54%
Incyte Corporation stock logo
INCY
Incyte
0.00%+6.37%+8.62%+31.55%+50.29%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+3.80%+27.14%+30.55%+41.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$275.954.46% Upside
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,118.2811.01% Upside
Incyte Corporation stock logo
INCY
Incyte
2.48
Hold$123.10-3.71% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.62
Moderate Buy$801.70-3.30% Downside

Current Analyst Ratings Breakdown

Latest INCY, ABBV, REGN, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$298.00 ➝ $303.00
8/20/2026
Incyte Corporation stock logo
INCY
Incyte
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Incyte Corporation stock logo
INCY
Incyte
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$152.00
8/20/2026
Incyte Corporation stock logo
INCY
Incyte
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$150.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,030.00 ➝ $1,095.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,200.00 ➝ $1,230.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,025.00 ➝ $1,100.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,050.00 ➝ $1,150.00
8/18/2026
argenex SE stock logo
ARGX
argenex
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$932.00 ➝ $1,200.00
8/18/2026
argenex SE stock logo
ARGX
argenex
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$940.00 ➝ $1,202.00
(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.63$15.10 per share17.49($1.83) per share-144.36
argenex SE stock logo
ARGX
argenex
$4.25B14.84$20.67 per share48.74$118.34 per share8.51
Incyte Corporation stock logo
INCY
Incyte
$5.82B4.45$6.18 per share20.68$26.32 per share4.86
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.95$41.72 per share19.87$295.66 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5474.7516.350.889.80%-422.07%14.34%10/30/2026 (Estimated)
argenex SE stock logo
ARGX
argenex
$1.29B$26.0438.7927.211.0832.19%43.59%36.66%N/A
Incyte Corporation stock logo
INCY
Incyte
$1.29B$7.8516.2915.864.0527.71%29.93%22.88%10/27/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.4916.411.4227.86%13.47%10.34%10/28/2026 (Estimated)

Latest INCY, ABBV, REGN, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/28/2026Q2 2026
Incyte Corporation stock logo
INCY
Incyte
$2.15$3.09+$0.94$2.81$1.50 billion$1.67 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.61%+6.80%195.48%53 Years
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.45%N/A9.29%N/A

Latest INCY, ABBV, REGN, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.83%7/15/20267/15/20268/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Incyte Corporation stock logo
INCY
Incyte
N/A
4.59
4.51
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
argenex SE stock logo
ARGX
argenex
60.32%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
argenex SE stock logo
ARGX
argenex
2.43%
Incyte Corporation stock logo
INCY
Incyte
16.20%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844202.70 million169.86 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-regeneron-class-action-lawsuit--hagens-berman-sobol-shapiro-llp-302858462.html
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3349913/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-sbs-law.html
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3349890/3080/en/levi-korsinsky-reminds-regeneron-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-14-2026-regn.html
3,000 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Maxi Investments CY Ltd
August 24 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3000-shares-in-regeneron-pharmaceuticals-inc-regn-bought-by-maxi-investments-cy-ltd-2026-08-24/
Sanctuary Advisors LLC Acquires Shares of 39,923 Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 6:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sanctuary-advisors-llc-acquires-shares-of-39923-regeneron-pharmaceuticals-inc-regn-2026-08-24/
Polymer Capital Management HK LTD Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-polymer-capital-management-hk-ltd-purchases-new-stake-in-regeneron-pharmaceuticals-inc-regn-2026-08-24/
5,489 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Te Ahumairangi Investment Management Ltd
August 24 at 6:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-5489-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-te-ahumairangi-investment-management-ltd-2026-08-24/
18,488 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Varma Mutual Pension Insurance Co
August 24 at 5:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-18488-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-varma-mutual-pension-insurance-co-2026-08-24/
Daiichi Life Insurance Co. Ltd. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-daiichi-life-insurance-co-ltd-takes-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-24/
Commerce Bank Purchases Shares of 7,131 Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-commerce-bank-purchases-shares-of-7131-regeneron-pharmaceuticals-inc-regn-2026-08-24/
EP Wealth Advisors LLC Invests $811,000 in Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ep-wealth-advisors-llc-invests-811000-in-regeneron-pharmaceuticals-inc-regn-2026-08-24/
Biondo Investment Advisors LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. $REGN
August 24 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-biondo-investment-advisors-llc-buys-new-shares-in-regeneron-pharmaceuticals-inc-regn-2026-08-24/
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
August 23 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/23/3349416/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Kendall Capital Management Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 6:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-kendall-capital-management-purchases-new-shares-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
Korea Investment CORP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 5:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-korea-investment-corp-makes-new-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
Vise Technologies Inc. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vise-technologies-inc-takes-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
Clear Harbor Asset Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-clear-harbor-asset-management-llc-makes-new-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
Bank of Nova Scotia Makes New $113.30 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-nova-scotia-makes-new-11330-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
B. Metzler seel. Sohn & Co. AG Invests $2.79 Million in Regeneron Pharmaceuticals, Inc. $REGN
August 23 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-invests-279-million-in-regeneron-pharmaceuticals-inc-regn-2026-08-23/
Oil Shipper Hits New High; Three Stocks Also Near Pivots
August 23 at 1:14 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/2a133701-4e49-33b4-9acf-36c6d82b0fe4/oil-shipper-hits-new-high%3B.html
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
August 22 at 7:16 AM  |  newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
AbbVie logo on a curved wall in an office lobby, with a laboratory and vials visible nearby.
AbbVie Quietly Solved Its Biggest Problem—Now What?
By Thomas Hughes | August 2, 2026
A candlestick stock price chart overlaid on a blurred urban skyline at dusk.
MarketBeat Week in Review – 08/03 - 08/07
By Chris Markoch | August 8, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$264.18 -0.78 (-0.29%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

argenex stock logo

argenex NASDAQ:ARGX

$1,007.40 -32.38 (-3.11%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Incyte stock logo

Incyte NASDAQ:INCY

$127.84 +0.03 (+0.02%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$829.08 -4.97 (-0.60%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas